Summit Therapeutics plc Notice Of Q3 Results

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Summit Therapeutics to Report Financial Results for the Third Quarter 
and Nine Months Ended 31 October 2019 on 17 December 2019 
 
   Oxford, UK, and Cambridge, MA, US, 16 December 2019 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism 
antibiotic innovation, will announce its financial results for the third 
quarter and nine months ended 31 October 2019 on 17 December 2019. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)          Tel:               44 (0)1235 443 951 
Michelle Avery (US office)                                            +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                       Tel:              +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                       Tel:              +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer, Corporate Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint Broker)       Tel:              +44 (0)20 7332 2500 
Phil Walker / Dominic Wilson 
MSL Group (US)                                  Tel:                  +1 781 684 6652 
                                                           mailto:summit@mslgroup.com 
Erin Anthoine                                                     summit@mslgroup.com 
                                                       ------------------------------ 
 
Consilium Strategic Communications (UK)         Tel:              +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart / Sukaina Virji         mailto:summit@consilium-comms. 
                                                       com 
                                                       summit@consilium-comms.com 
                                                       ------------------------------ 
Lindsey Neville 
 
 
   -END-

(END) Dow Jones Newswires

December 16, 2019 09:15 ET (14:15 GMT)

Summit Therapeutics (LSE:SUMM)
過去株価チャート
から 12 2024 まで 1 2025